Dermaroller (Microneedling) and Minoxidil: Does It Improve Results in Androgenetic Alopecia?

Two explanations are proposed and they are not mutually exclusive. The first assumes that microneedling triggers a controlled wound-healing response: release of growth factors, an influx of inflammatory cells and activation of pathways associated with hair growth, including the Wnt pathway, and stimulation of stem cells around the dermal papilla and part of the follicle bulge. The authors of the pilot study described below link the effect to stimulation of follicular stem cells and activation of growth factors. This is, however, a mechanism inferred from experimental and clinical research, not directly proven in humans.

The second explanation concerns absorption: microchannels in the stratum corneum may increase the penetration of topically applied substances, including minoxidil, which theoretically raises its concentration around the follicles. This hypothesis has a pharmacological rationale, but in clinical trials it is hard to separate its contribution from the effect of the injury itself. In practice it also means that minoxidil applied immediately after deep needling may be absorbed more strongly and irritate the skin more often — which is why many protocols recommend not applying it directly after the procedure (the findings on the interval come from practice, not from comparative studies).

This is the study that started the wave of interest in the topic, and it is the one usually cited in popular descriptions of the method. The difference seems large — more than a fourfold greater gain in hair count — but its context must be remembered: the study was a pilot, short and conducted at one centre, and patients knew which method they were using. Patients undergoing a procedure that hurts and takes time may expect better results and report them, which strengthens subjective outcomes. Fortunately the main outcome was hair count in a fixed area, less prone to such distortion.

Two independent meta-analyses give a consistent picture: the combination is better than minoxidil alone in terms of hair count. In a network meta-analysis of 27 trials (1,110 patients), minoxidil 5% with microneedling ranked first for efficacy at 24 weeks, and its advantage over minoxidil alone averaged 13 hairs per cm². For comparison, minoxidil with platelet-rich plasma (PRP) was second, and microneedling alone ranked lower than minoxidil alone.

The pilot study with which it all began used weekly microneedling (in the protocol description in our entry on the dermaroller: 1.5 mm needles), a scheme repeated in many protocols. Later studies differed in needle length and in intervals between procedures, which is why the meta-analysis singled out subgroups by depth (≤1 mm and >1 mm). The 2025 meta-analysis showed no significant difference in hair count between depths ≤1 mm and >1 mm, which is important practical information: deeper needles did not prove more effective, and they increase the risk of complications.

At home the recommended needle length is usually 0.25–0.5 mm and the procedure every 1–2 weeks, with an interval that lets the skin regenerate. Needles of 1 mm and longer are regarded as a clinic procedure, performed with sterility and training. Consequence for the patient: if you are considering microneedling as an addition to minoxidil, there is no evidence today that you must reach for deeper needles to benefit. At the same time we do not know whether very short home needles give the same effect as in the studies, which often used longer ones — this gap in knowledge is an honest limitation.

Time matters: in the studies effects were assessed after 12–24 weeks, and the response to minoxidil develops over months (often with an initial temporary increase in shedding in the first weeks). The method should therefore not be judged after a month. It is worth photographing the same scalp areas in constant conditions every 4–8 weeks to assess changes objectively.

The punctures break the epidermal barrier and reach the vascularized dermis, which means contact with blood and tissue fluids. In practice the most common adverse effects are redness, tenderness, slight pinpoint bleeding, flaking and short-lived irritation from minoxidil; in the meta-analyses they were judged mild and self-limiting, and one reported no scarring or serious events. The risk is, however, not zero: bacterial infections can result from an unclean instrument or a procedure on damaged skin.

This case does not mean microneedling is dangerous for everyone; it means it is an invasive procedure and requires hygiene. Basic rules: each roller is for one person, it is disinfected before and after use according to the manufacturer's instructions (70% isopropyl alcohol), replaced every few weeks or at the first signs of needle dulling, hands and scalp are washed before the procedure, and the procedure is not performed on skin with wounds, rash or inflammation. People with weakened immunity or clotting disorders should consult a doctor.

The second popular myth is the belief that microneedling alone replaces treatment. In the network meta-analysis microneedling alone ranked below minoxidil alone, and its advantage appeared only in combination with the drug. It does not block DHT and does not treat the cause of androgenetic alopecia, so it is best treated as a possible supplement, not as stand-alone therapy.

A dermaroller with minoxidil is one of the few ‘home add-ons’ with a decent set of randomized trials and meta-analyses behind it — which sets it apart from many fashionable methods with no data at all. At the same time it is a method with a moderate effect of uncertain size, with a risk that can be limited by hygiene and a sensible choice of needles. The best strategy is to treat it as a supplement to treatment of proven action, start with short needles, assess the effect objectively and not reach for deeper procedures on your own.